Selected studies in stage III to IV NLPHL
| . | n . | Median follow-up, y . | Treatment . | Outcome (%) . | OS (%) . | ||
|---|---|---|---|---|---|---|---|
| Diehl et al, 19991 | 44 | 6.8 | CHT or CMT* | 8 y | FFTP | Stage III, 62 | Stage III, 94 (DSS) |
| Stage IV, 24 | Stage IV, 41 (DSS) | ||||||
| Nogova et al, 200819 | 83 | 4.2 | CMT† | 4.2 y | FFTF | 77 | 96 |
| Canellos et al, 201050 | 37 | NA | 32%, ABVD or EVA | “Failure” | 75 | NA | |
| 68%, MOPP+/ABVD | “Failure” | 32 | NA | ||||
| Fanale et al, 201051 | 12 | 3.5 | RCHOP +/IFRT | 5 y | PFS | 95 | 95 |
| Xing et al, 201249 | 42 | 10 | 83%, ABVD | 10 y | FFTF | 76 | 86 |
| . | n . | Median follow-up, y . | Treatment . | Outcome (%) . | OS (%) . | ||
|---|---|---|---|---|---|---|---|
| Diehl et al, 19991 | 44 | 6.8 | CHT or CMT* | 8 y | FFTP | Stage III, 62 | Stage III, 94 (DSS) |
| Stage IV, 24 | Stage IV, 41 (DSS) | ||||||
| Nogova et al, 200819 | 83 | 4.2 | CMT† | 4.2 y | FFTF | 77 | 96 |
| Canellos et al, 201050 | 37 | NA | 32%, ABVD or EVA | “Failure” | 75 | NA | |
| 68%, MOPP+/ABVD | “Failure” | 32 | NA | ||||
| Fanale et al, 201051 | 12 | 3.5 | RCHOP +/IFRT | 5 y | PFS | 95 | 95 |
| Xing et al, 201249 | 42 | 10 | 83%, ABVD | 10 y | FFTF | 76 | 86 |
ABVD, adriamycin, bleomycin, vinblastine, and dacarbazine; BEACOPP, bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone; COPP, cyclophosphamide, vincristine, procarbazine, and prednisone; DSS, disease-specific survival; EVA, etoposide, vinblastine, and adriamycin; IMEP, isophosphamide, methotrexate, etoposide, and prednisone; MOPP, mechlorethamine, vincristine, procarbazine, and prednisone; NA, not reported/not available; RCHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
CHT, chemotherapy; MOPP-, ABVD-, or MOPPABVD-like.
CMT; radiotherapy and COPP/ABV (doxorubicin, bleomycin, and vincristine)/IMEP, COPP/ABVD, or BEACOPP.